Our Role
Elliogen is not an exploitant.
We operate as an independent, conflict-free advisor, bridging pharmaceutical companies with licensed exploitants in France. We help define the optimal market-entry model, identify the right partners, and avoid costly regulatory and commercial pitfalls.
Services
French Market Entry Plan
Include:
- Exploitant strategy
- Distributor shortlist
- Pricing / access approach
- Key risks
Business Development
We advise on partnership strategy and execution, from partner identification to early commercial discussions.
Our focus is on structuring sustainable collaborations aligned with both regulatory requirements and long-term commercial objectives.
Early Access Programs (EAP)
We provide end-to-end strategic support for Early Access Programs, ensuring regulatory alignment, operational readiness, and a clear pathway to future commercialisation — with patient access at the core.
Elliogen works with pharmaceutical companies entering or expanding in France and Europe, particularly where questions around exploitant models, partner selection, and regulatory responsibilities arise.
Not sure whether you need an exploitant — or which one?
Elliogen helps pharmaceutical companies assess the right market-entry model and connect with trusted Exploitant partners in France.
